Bayer Pharma Aktiengesellschaft

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Paul Matthew Blaney

Hartmut Rehwinkel

Katja Zimmermann

Duy Nguyen

Roland Neuhaus

Marcus Bauser

Sonja Anlauf

Olaf Panknin

Stefan Kaulfuss

Wolfgang Schwede

Sven Ring

Holger Siebeneicher

Gianna Toschi

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Benzimidazol-2-amines as mIDH1 inhibitors

The present invention relates to benzimidazol-2-amines of general formula (I) in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

Growing community of inventors

Glossop, United Kingdom

Paul Matthew Blaney